GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

The FTSE 100 index closed down 21.29 points, 0.2%, at 8,717.97. The FTSE 250 ended down 90.94 points, 0.4%, at 20,708.72, and the AIM All-Share closed down 0.70 points, 0.1%, at 736.04. The Cboe UK ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...